Decreased COPD prevalence in Sweden after decades of decrease in smoking.
COPD
Epidemiology
Population study
Prevalence
Risk
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
10
07
2020
accepted:
06
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
21
8
2021
Statut:
epublish
Résumé
COPD has increased in prevalence worldwide over several decades until the first decade after the millennium shift. Evidence from a few recent population studies indicate that the prevalence may be levelling or even decreasing in some areas in Europe. Since the 1970s, a substantial and ongoing decrease in smoking prevalence has been observed in several European countries including Sweden. The aim of the current study was to estimate the prevalence, characteristics and risk factors for COPD in the Swedish general population. A further aim was to estimate the prevalence trend of COPD in Northern Sweden from 1994 to 2009. Two large random population samples were invited to spirometry with bronchodilator testing and structured interviews in 2009-2012, one in south-western and one in northern Sweden, n = 1839 participants in total. The results from northern Sweden were compared to a study performed 15 years earlier in the same area and age-span. The diagnosis of COPD required both chronic airway obstruction (CAO) and the presence of respiratory symptoms, in line with the GOLD documents since 2017. CAO was defined as post-bronchodilator FEV Based on the fixed ratio definition, the prevalence of COPD was 7.0% (men 8.3%; women 5.8%) in 2009-2012. The prevalence of moderate to severe (GOLD ≥ 2) COPD was 3.5%. The LLN based results were about 30% lower. Smoking, occupational exposures, and older age were risk factors for COPD, whereof smoking was the most dominating risk factor. In northern Sweden the prevalence of COPD, particularly moderate to severe COPD, decreased significantly from 1994 to 2009, and the decrease followed a decrease in smoking. The prevalence of COPD has decreased in Sweden, and the prevalence of moderate to severe COPD was particularly low. The decrease follows a major decrease in smoking prevalence over several decades, but smoking remained the dominating risk factor for COPD.
Sections du résumé
BACKGROUND
BACKGROUND
COPD has increased in prevalence worldwide over several decades until the first decade after the millennium shift. Evidence from a few recent population studies indicate that the prevalence may be levelling or even decreasing in some areas in Europe. Since the 1970s, a substantial and ongoing decrease in smoking prevalence has been observed in several European countries including Sweden. The aim of the current study was to estimate the prevalence, characteristics and risk factors for COPD in the Swedish general population. A further aim was to estimate the prevalence trend of COPD in Northern Sweden from 1994 to 2009.
METHODS
METHODS
Two large random population samples were invited to spirometry with bronchodilator testing and structured interviews in 2009-2012, one in south-western and one in northern Sweden, n = 1839 participants in total. The results from northern Sweden were compared to a study performed 15 years earlier in the same area and age-span. The diagnosis of COPD required both chronic airway obstruction (CAO) and the presence of respiratory symptoms, in line with the GOLD documents since 2017. CAO was defined as post-bronchodilator FEV
RESULTS
RESULTS
Based on the fixed ratio definition, the prevalence of COPD was 7.0% (men 8.3%; women 5.8%) in 2009-2012. The prevalence of moderate to severe (GOLD ≥ 2) COPD was 3.5%. The LLN based results were about 30% lower. Smoking, occupational exposures, and older age were risk factors for COPD, whereof smoking was the most dominating risk factor. In northern Sweden the prevalence of COPD, particularly moderate to severe COPD, decreased significantly from 1994 to 2009, and the decrease followed a decrease in smoking.
CONCLUSIONS
CONCLUSIONS
The prevalence of COPD has decreased in Sweden, and the prevalence of moderate to severe COPD was particularly low. The decrease follows a major decrease in smoking prevalence over several decades, but smoking remained the dominating risk factor for COPD.
Identifiants
pubmed: 33115506
doi: 10.1186/s12931-020-01536-4
pii: 10.1186/s12931-020-01536-4
pmc: PMC7594463
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
283Références
COPD. 2018 Oct;15(5):454-463
pubmed: 30475654
Eur Respir J. 2011 Dec;38(6):1261-77
pubmed: 22130763
Eur Respir J. 2006 Sep;28(3):523-32
pubmed: 16611654
Eur Respir J. 2010 Oct;36(4):766-73
pubmed: 20693258
Eur Clin Respir J. 2015 Jul 20;2:
pubmed: 26557250
Respir Med. 2006 Feb;100(2):264-72
pubmed: 15975774
Am J Respir Crit Care Med. 2020 Mar 15;201(6):671-680
pubmed: 31770495
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889106
Respir Med. 2013 Jul;107(7):1037-45
pubmed: 23680166
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
Eur Respir J. 2010 Oct;36(4):758-65
pubmed: 19996189
Lancet. 2015 Mar 14;385(9972):966-76
pubmed: 25784347
Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551
pubmed: 29406779
Proc Am Thorac Soc. 2011 Aug;8(4):363-7
pubmed: 21816993
Chest. 2000 May;117(5 Suppl 2):354S-9S
pubmed: 10843976
Eur Respir J. 2017 Jun 22;49(6):
pubmed: 28642306
Clin Respir J. 2012 Apr;6(2):120-7
pubmed: 21651748
J Glob Health. 2015 Dec;5(2):020415
pubmed: 26755942
Respir Med. 2009 Dec;103(12):1807-15
pubmed: 19695859
Am J Respir Crit Care Med. 2013 Apr 1;187(7):728-35
pubmed: 23392440
Chest. 2014 Jun;145(6):1298-1304
pubmed: 24356778
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Respiration. 2005 Sep-Oct;72(5):471-9
pubmed: 16210885
Respir Med. 2003 Feb;97(2):115-22
pubmed: 12587960
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604
pubmed: 20522794
J Epidemiol Community Health. 2000 Dec;54(12):917-22
pubmed: 11076988
COPD. 2005 Sep;2(3):331-9
pubmed: 17146998
Am J Respir Crit Care Med. 2007 Jan 1;175(1):32-9
pubmed: 17008642
Respir Med. 2015 Nov;109(11):1439-45
pubmed: 26440676
Chest. 2006 Apr;129(4):879-85
pubmed: 16608933
Am J Respir Crit Care Med. 2014 May 1;189(9):1022-30
pubmed: 24552242
Respir Med. 2018 May;138:50-56
pubmed: 29724393
Thorax. 2009 Oct;64(10):863-8
pubmed: 19553233
Eur Respir J. 2009 Sep;34(3):588-97
pubmed: 19460786
Chest. 2013 May;143(5):1395-1406
pubmed: 23715520
Respir Med. 2011 Mar;105(3):410-7
pubmed: 20952174
Chest. 2005 May;127(5):1544-52
pubmed: 15888826
Respir Med. 2016 May;114:103-10
pubmed: 27109819
Eur Respir J. 2010 Dec;36(6):1496-8
pubmed: 21119213
Chest. 2000 Oct;118(4):981-9
pubmed: 11035667
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Chest. 2000 May;117(5 Suppl 2):339S-45S
pubmed: 10843974
Chest. 2007 Nov;132(5):1608-14
pubmed: 17998360
Health Rep. 2014 Mar;25(3):3-11
pubmed: 24648134
Am J Respir Crit Care Med. 2003 Mar 1;167(5):787-97
pubmed: 12598220
Chest. 2014 May;145(5):992-997
pubmed: 24264472